Simultaneous determination of pyrimethamine, sulfadiazine and N-acetyl-sulfadiazine in plasma for monitoring infants in treatment of congenital toxoplasmosis.
A method for the simultaneous determination of pyrimethamine, sulfadiazine and its metabolite N-acetyl-sulfadiazine in small plasma samples from neonates in treatment for congenital toxoplasmosis has been developed. In this method only 25 microl of plasma is used and a simple sample preparation based on protein precipitation and centrifugation provides highly reliable data as the recovery is about 100% and the precision is good. The analysis is performed using high performance liquid chromatography with UV and mass spectrometric (MS) detection. Pyrimethamine was found to give a linear response using MS detection in the range 0.02-5 microg/ml. Sulfadiazine and its metabolite N-acetyl-sulfadiazine were preferably analysed by UV at 269 nm in the concentration ranges 0.2-200 microg/ml for sulfadiazine and 0.2-50 microg/ml for N-acetyl-sulfadiazine.
Johannessen
Jane Krogh
JK
Department of Analytical Chemistry, The Danish University of Pharmaceutical Sciences, Universitetsparken 2, DK-2100 Copenhagen, Denmark.
Christiansen
Ida
I
Schmidt
Dorte Remmer
DR
Petersen
Eskild
E
Hansen
Steen Honoré
SH
D002851:Chromatography, High Pressure Liquid / Q000379:methods; D016903:Drug Monitoring / Q000379:methods*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D013058:Mass Spectrometry / Q000379:methods; D011739:Pyrimethamine / Q000097:blood* / Q000627:therapeutic use; D013056:Spectrophotometry, Ultraviolet / Q000379:methods; D013411:Sulfadiazine / Q000097:blood* / Q000627:therapeutic use; D014125:Toxoplasmosis, Congenital / Q000097:blood* / Q000188:drug therapy
D013411:Sulfadiazine; D011739:Pyrimethamine